2. UroToday Home
  3. Trials in Progress

Trials in Progress

The Efficacy and Safety of Darolutamide plus ADT in mHSPC (ARASEC)

Trials in Progress
Videos

Open-label Study of Androgen Receptor Inhibition With dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm

  • Condition: Metastatic Hormone-sensitive Prostate Cancer
  • Study ID: NCT05059236
ACTIVE, NOT RECRUITING
Physician-Scientist Review Articles
State of the Evidence Review Articles
Written by Rashid K. Sayyid, MD, MSc & Zachary Klaassen, MD, MSc
August 17, 2022
The treatment landscape of advanced prostate cancer continues to evolve, particularly over the last 5+ years. Although there are several treatment options, including both ADT-based doublet and triplet combinations, available for men with metastatic hormone
Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Neal Shore, MD, FACS
The 2023 ASCO annual meeting included a prostate cancer session, featuring a trials-in-progress presentation by Dr. Neal Shore discussing ARASEC, an open-label study of darolutamide plus ADT vs ADT in metastatic hormone-sensitive prostate cancer (mHSPC) using an external control arm.
Presented by Neal D. Shore, MD, FACS
(UroToday.com) The 2023 GU ASCO annual meeting included a session on trials in progress for prostate cancer, featuring a presentation by Dr. Neal Shore discussing the trial design of ARASEC, an open-label single-arm study with an external control of darolutamide plus ADT versus ADT in metastatic hormone-sensitive prostate cancer.
Presented by Neal D. Shore, MD, FACS
The 2022 ASCO annual meeting featured a session on prostate cancer, including a trial in progress presentation by Dr. Neal Shore discussing ARASEC, an open-label study of androgen receptor inhibition with darolutamide + ADT versus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC) using an external control arm.